veltuzumab   Click here for help

GtoPdb Ligand ID: 8268

Synonyms: hA20 | IMMU-106
Immunopharmacology Ligand
Compound class: Antibody
Comment: Veltuzumab is a humanized monoclonal antibody targeting CD20. With the exeption of Asp101 in the complementarity-determining region 3 (CDR3) of the antibody's variable heavy chain, its CDRs are identical to rituximab [2]. This single amino acid substitution appears to account for veltuzumab's reduced off-rate compared to rituximab [2] as well as its enhanced capacity to induce antibody-dependent cellular cytotoxicity (ADCC), and complement-mediated cytotoxicity.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. (2005)
The biology of CD20 and its potential as a target for mAb therapy.
Curr Dir Autoimmun, 8: 140-74. [PMID:15564720]
2. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. (2009)
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Blood, 113 (5): 1062-70. [PMID:18941114]
3. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al.. (2010)
CD20 deficiency in humans results in impaired T cell-independent antibody responses.
J Clin Invest, 120 (1): 214-22. [PMID:20038800]
4. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Clin Cancer Res, 10 (8): 2868-78. [PMID:15102696]